Aisling Capital Management as of Dec. 31, 2021
Portfolio Holdings for Aisling Capital Management
Aisling Capital Management holds 21 positions in its portfolio as reported in the December 2021 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Bridgebio Pharma (BBIO) | 35.7 | $101M | 6.1M | 16.68 | |
| Monte Rosa Therapeutics (GLUE) | 10.6 | $30M | 1.5M | 20.42 | |
| Syndax Pharmaceuticals (SNDX) | 7.9 | $22M | 1.0M | 21.89 | |
| Nuvation Bio Com Cl A (NUVB) | 7.6 | $22M | 2.5M | 8.50 | |
| Elevation Oncology (ELEV) | 6.0 | $17M | 2.8M | 6.02 | |
| Harmony Biosciences Hldgs In (HRMY) | 5.3 | $15M | 355k | 42.64 | |
| Talaris Therapeutics | 3.7 | $10M | 683k | 15.29 | |
| Aclaris Therapeutics (ACRS) | 3.3 | $9.2M | 635k | 14.54 | |
| Verona Pharma Sponsored Ads (VRNA) | 3.2 | $9.0M | 1.3M | 6.72 | |
| Aeglea Biotherapeutics | 2.8 | $8.0M | 1.7M | 4.75 | |
| Reneo Pharmaceuticals (RPHM) | 2.7 | $7.6M | 886k | 8.55 | |
| Poseida Therapeutics I (PSTX) | 2.5 | $7.1M | 1.0M | 6.81 | |
| Biomea Fusion (BMEA) | 2.1 | $6.0M | 799k | 7.45 | |
| Spruce Biosciences (SPRB) | 1.9 | $5.4M | 1.2M | 4.46 | |
| Avrobio Ord (AVRO) | 1.4 | $3.9M | 1.0M | 3.85 | |
| Marker Therapeutics Ord | 1.1 | $3.0M | 3.1M | 0.95 | |
| Obseva Sa | 1.0 | $2.8M | 1.4M | 1.99 | |
| Zosano Pharma Corporation Com New | 0.5 | $1.3M | 2.7M | 0.47 | |
| Atreca Cl A Com (BCEL) | 0.4 | $1.2M | 388k | 3.03 | |
| Viracta Therapeutics (VIRX) | 0.4 | $1.1M | 289k | 3.65 | |
| Nabriva Therapeutics SHS | 0.0 | $114k | 191k | 0.60 |
